论文部分内容阅读
目的探讨急性冠脉综合征(ACS)患者厄贝沙坦治疗前后血巨噬细胞炎性蛋白1α(MIP-1α)、血栓调节蛋白(TM)、血小板活化因子(PAF)及可溶性CD40配体(sCD40L)水平及临床意义。方法采用ELISA法测定86例ACS患者、52例健康对照者血清中MIP-1α、TM、PAF及sCD40L浓度,ACS患者随机分常规(40例)和厄贝沙坦(46例)治疗组,治疗8周后再次测定血MIP-1α、TM、PAF及sCD40L含量。结果血MIP-1α、TM、PAF和sCD40L水平ACS组明显高于对照组(P<0.05),ACS患者治疗8周后MIP-1α、TM、PAF和sCD40L水平均明显下降(P<0.05),且厄贝沙坦组下降明显(P<0.05)。结论 ACS的发生与MIP-1α、TM、PAF和sCD40L有关,厄贝沙坦可降低血MIP-1α、TM、PAF和sCD40L水平,在抑制动脉粥样病变的炎症反应,保护血管内皮方面有一定作用。
Objective To investigate the expression of MIP-1α, thrombomodulin (TM), platelet activating factor (PAF) and soluble CD40 ligand (IL-1β) in patients with acute coronary syndrome sCD40L) levels and clinical significance. Methods Serum levels of MIP-1α, TM, PAF and sCD40L in 86 patients with ACS and 52 healthy controls were measured by ELISA. ACS patients were randomly divided into routine (n = 40) and irbesartan (n = 46) Eight weeks later, the levels of blood MIP-1α, TM, PAF and sCD40L were determined again. Results The levels of serum MIP-1α, TM, PAF and sCD40L in ACS group were significantly higher than those in control group (P <0.05). The levels of MIP-1α, TM, PAF and sCD40L in ACS patients were significantly decreased And irbesartan group decreased significantly (P <0.05). Conclusions The occurrence of ACS is related to MIP-1α, TM, PAF and sCD40L. Irbesartan can reduce the level of MIP-1α, TM, PAF and sCD40L in blood and inhibit the inflammatory reaction of atherosclerosis and protect vascular endothelium effect.